1. Государственный реестр лекарственных средств. Запрос «гидроксихлорохин», поиск по МНН [Electronic resource]. URL: https://grls.rosminzdrav.ru/grls.aspx?s=гидроксихлорохин&m=mnn (accessed: 24.05.2020).
2. Государственный реестр лекарственных средств. Плаквенил. Инструкция по медицинскому применению [Electronic resource]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=dd41b667c371-45bb-b9d0-f7053eab7c3d&t= (accessed: 17.05.2020).
3. Yao X. et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. DOI: 10.1093/cid/ciaa237
4. Vincent MJ et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69. DOI: 10.1186/1743-422X-2-69
5. Keyaerts E et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8. DOI: 10.1016/j.bbrc.2004.08.085
6. Devaux CA et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May;55(5):105938. DOI: 10.1016/j.ijantimicag.2020.105938
7. Sahraei Z et al. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020 Apr;55(4):105945. DOI: 10.1016/j.ijantimicag.2020.105945
8. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670. DOI: 10.1093/jac/dkaa114
9. Coronavirus (COVID-19) Update: FDA Reiterates Importance of Close Patient Supervision for ‘Off-Label’ Use of Antimalarial Drugs to Mitigate Known Risks, Including Heart Rhythm Problems [Electronic resource]. URL: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-reiterates-importance-close-patientsupervision-label-use (accessed: 24.05.2020).
10. Временные методические рекомендации Министерства здравоохранения РФ по профилактике, диагностике и лечению новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020) [Электронный ресурс]. 2020. Доступно по: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_МR_COVID-19_v6.pdf Ссылка активна на 25.05.2020
11. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Electronic resource]. URL: https://www.covid19treatmentguidelines.nih.gov/ (accessed: 25.05.2020).
12. UW Medicine COVID-19 Resource Site [Electronic resource] // University of Washington. 2020. URL: https://covid-19.uwmedicine.org/Pages/default.aspx (accessed: 25.05.2020).
13. Tang W et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. MedRxiv. 2020. DOI: 10.1101/2020.04.10.20060558
14. Mahevas M et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. MedRxiv. April 14, 2020. DOI: 10.1101/2020.04.10.20060699
15. Brigham and Women’s Hospital COVID-19 Clinical Guidelines [Electronic resource]. URL: https://covidprotocols.org/ (accessed: 25.05.2020).
16. Colleges C.A.M. and N. National COVID-19 Clinical Evidence Taskforce [Electronic resource]. 2020. P. Guidelines. URL: https://covid19evidence.net.au/ (accessed: 25.05.2020).
17. Coronavirus (COVID-19): latest guidance for medicines safety — GOV.UK [Electronic resource]. URL: https://www.gov.uk/drugsafety-update/coronavirus-covid-19-latest-guidance-for-medicinessafety#chloroquine-and-hydroxychloroquine (accessed: 25.05.2020).
18. Search of: Hydroxychloroquine treatment | COVID-19 — List Results — ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/results?term=Hydroxychloroquine+treatment&cond=COVID-19&Search=Apply&age_v=&gndr=&type=&rslt= (accessed: 25.05.2020).
19. Mehra MR et al. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 May 22;S0140-6736(20)31180-6. DOI: 10.1016/S0140-6736(20)31180-6
20. Singh AK et al. “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”. Diabetes Metab Syndr. Jul-Aug 2020;14(4):589-596. DOI: 10.1016/j.dsx.2020.05.017
21. Gérard A et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. Jul-Aug 2020;75(4):371-379. DOI: 10.1016/j.therap.2020.05.002
22. FDA Drug Safety Communication: FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. URL: https://www.fda.gov/media/137250/download (accessed: 25.05.2020).
23. HRS COVID-19 Task Force Update: April 21, 2020 URL: https://www.hrsonline.org/COVID19-Challenges-Solutions/hrscovid-19-task-force-update-april-21-2020 (accessed: 25.05.2020).
24. Timothy F. Simpson, MD, PharmD; Richard J. Kovacs, MD, FACC; and Eric C. Stecker, MD, MPH, FACC. American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycintreatment-for-covid-19 (accessed: 25.05.2020).
25. Giudicessi JR et al. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin Proc. 2020 Jun;95(6):1213-1221. DOI: 10.1016/j.mayocp.2020.03.024
26. Jordan M Prutkin, MD, Bradley P Knight, Brian C Downey. Coronavirus disease 2019 (COVID-19): Arrhythmias and conduction system disease. https://www.uptodate.com/contents/coronavirusdisease-2019-covid-19-arrhythmias-and-conduction-systemdisease#H3480858110 (accessed: 25.05.2020).
